All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ETD002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $96.8 milion
Deal Type: Acquisition October 07, 2020
Details:
Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Itolizumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EQ001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
These findings suggest the CD6-ALCAM pathway may contribute in multiple ways to asthma pathology. These data support Equillium’s ongoing clinical development of itolizumab for the treatment of patients with moderateto-severe uncontrolled asthma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATYR1923
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KRP-R120
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: KYORIN PHARMACEUTICAL CO LTD
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Kyorin Holdings has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submission.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARINA-1
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: White Rock Capital Management
Deal Size: $8.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 18, 2020
Details:
Funds to be used for the development and clinical programs associated with Renovion's lead therapeutic candidate ARINA-1. ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TRV027
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
Details:
Collaboration to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALT-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2020
Details:
The funding is based on the company's progress in completion of the initial Fastrack Phase I studies of its novel immune-based anti-inflammatory therapeutic antibody for critically ill patients with acute lung injury.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cord Blood-Derived T-Regulatory Cells
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome (ARDS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BM-Allo.MSC
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Setanaxib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
This Phase 1 study will evaluate setanaxib at doses up to 1600 mg/day in up to 54 subjects. Genkyotex is currently discussing the registration strategy for setanaxib in PBC with FDA and EMA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gimsilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
Details:
Roivant Sciences and Altasciences are workig together for the development of gimsilumab as a potential treatment for SARS CoV-2 related acute respiratory distress syndrome.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
